Hamlet BioPharma

Hamlet BioPharma AB is a pharmaceutical company with strong links to research, working with natural and biological substances. The company was formed through the merger of two pharmaceutical companies, Hamlet Pharma AB and SelectImmune Pharma AB, and is listed on the Spotlight Stock Market. Hamlet BioPharma is a formidable pharmaceutical company specializing in the development of drugs for the treatment of cancer and infectious diseases. The company has a portfolio of a total of ten drug projects, three of which are in Phase II, with positive results in clinical trials for two of these projects. The portfolio encompasses a total of eleven patent families covering cancer, infections, and tuberculosis, with over 60 patents. Hamlet BioPharma is currently establishing a focused commercial organization with access to a technology platform and researchers in a university environmen Phase I/II clinical trials in human patients with bladder cancer are currently underway. The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. (Human Alpha-lactalbumin Made LEthal to Tumor cells) HAMLET is a tumoricidal protein-lipid complex, formed by two GRAS (generally regarded as safe) molecules present in human milk. The novel therapeutic entity HAMLET is formed when the human milk protein alpha-lactalbumin undergoes a conformational change and binds to oleic acid. Advanced technologies allow us to see molecules, measure them from every angle, and understand their deepest secrets. Using such techniques, we were able to identify the structure of HAMLET and especially the domains that are responsible for the killing effect. This is how we identified the Alpha1 peptide, which forms a lipid complex and kills tumor cells. This smaller part of the HAMLET molecule can be produced synthetically, and used as a drug candidate.